Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. - Wikidata - awgldk - TriplyDB

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.

http://www.wikidata.org/entity/Q37632230

about

Targeted Lung Cancer Treatments and Eye Metastasis BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis.Biology and clinical significance of circulating tumor cell subpopulations in lung cancer Current Landscape of Targeted Therapy in Lung Cancer.Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

P2860

Q33566410-2FCDA400-F21E-4474-A669-435B516B061D Q41374639-D8B5B868-E59A-47E0-82D8-81232088933B Q41605032-B23F2C77-6ED6-4D09-91C8-7EA18C420731 Q46034707-A1B56442-D77E-49C7-A9BC-EFFFB2FFFF1F Q46071509-2F5E1C76-41EC-4143-8F48-732B084D171B Q48215912-CBC6EEFD-9302-4887-832B-694D9899E0FA Q55515297-C537979D-6523-4DB1-8CA6-C3E1F63BD578

P2860

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.

http://www.wikidata.org/entity/Q37632230

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Therapeutic approach to treati ...... nce and clinical implications.

@en

Therapeutic approach to treati ...... nce and clinical implications.

@nl

type

label

Therapeutic approach to treati ...... nce and clinical implications.

@en

Therapeutic approach to treati ...... nce and clinical implications.

@nl

prefLabel

Therapeutic approach to treati ...... nce and clinical implications.

@en

Therapeutic approach to treati ...... nce and clinical implications.

@nl

P1433

Q37632230-0C7F6F01-EF84-4D3A-9861-969C93F14CCF

P1476

Q37632230-E9695C1B-A48D-4883-A62A-1B60DE89030E

P2093

Q37632230-E31F78DE-EAC2-468F-A186-4796C207599E

Q37632230-E5345A3A-AC22-42A8-A74A-C5EC6ABD4A20

P2860

Q37632230-0004B7C5-9B25-4F10-92A1-EF162132ABC3

Q37632230-07719E3C-D1B0-440C-A6D2-64107090657D

Q37632230-12809512-FFCC-4F78-AD6B-B88EB74A7DD9

Q37632230-157C7FCC-7578-428D-BC1F-DC583B37E6B1

Q37632230-173FC30B-805D-4573-B0E4-29A3CC60A4A8

Q37632230-17513C82-9A9A-428E-92EB-0ED6AEB2250E

Q37632230-175C18CD-E4C5-49A1-BE70-AF01BCCA3501

Q37632230-19052A49-C107-459E-8801-3CDD6523951C

Q37632230-1951005C-90D8-460E-B44F-0A5A702F38B5

Q37632230-1A06727F-4DB0-4BB3-9856-B4EE96A8F1E1

P304

Q37632230-7944256B-5F4E-4787-B497-2159C1F925B1

P31

Q37632230-B9E3EBCF-D81B-4699-BE0A-0DCF7C59D5E0

P356

Q37632230-F516A201-B9CA-41CE-A716-E29E13E3A9D7

P433

Q37632230-8AF8B328-A347-4830-A529-640B74D2293A

P478

Q37632230-DCA011D4-0EBD-4DA7-BC72-677E5F92FB62

P577

Q37632230-4945C803-1CBD-4090-8715-3FE881D917C1

P698

Q37632230-508C75F0-B638-4F96-8EAA-6A791A6AEACB

P932

Q37632230-C54A194C-7FCD-40BD-8B8B-B044E428C8DA

P356

1758834016670555

P1433

Therapeutic advances in medical oncology

P1476

Therapeutic approach to treati ...... nce and clinical implications.

@en

P2093

Adrianus J de Langen

http://www.w3.org/2001/XMLSchema#string

Egbert F Smit

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Somatic mutations affect key pathways in lung adenocarcinoma

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

RAF inhibitors that evade paradoxical MAPK pathway activation

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

P304

46-58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834016670555

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28203297

http://www.w3.org/2001/XMLSchema#string

P932

5298452

http://www.w3.org/2001/XMLSchema#string